Dyax Corp. to Participate in the 2014 Wells Fargo Healthcare Conference
June 10 2014 - 8:00AM
Business Wire
Dyax Corp. (NASDAQ: DYAX) announced today that executive
management will participate in the Wells Fargo Healthcare
Conference being held June 17-18, 2014 at the InterContinental
Hotel in Boston, MA. The Company will present on Tuesday, June 17
at 10:35 AM (ET) and will provide a corporate update on the
Company’s key value drivers – the KALBITOR® (ecallantide) business,
DX-2930 and the LFRP.
This presentation will be webcast live and may be accessed by
visiting the Investor Relations section of the company website at
www.dyax.com. The webcast will also be available on the Dyax
website for a limited period of time following the conference.
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on
the discovery, development and commercialization of novel
biotherapeutics for unmet medical needs. The Company currently
markets KALBITOR® for the treatment of acute attacks of hereditary
angioedema (HAE) in patients 12 years of age and older. Dyax is
also developing DX-2930 for the prophylactic treatment of HAE.
Both KALBITOR and DX-2930 were identified using Dyax's patented
phage display technology. Dyax has broadly licensed this technology
and has a portfolio of product candidates being developed by its
licensees, which it refers to as the Licensing and Funded Research
Portfolio (LFRP). The Company is eligible to receive future
milestones and/or royalties dependent upon the development and
commercialization of these candidates. In April 2014, Dyax’s
licensee Lilly received FDA approval for CYRAMZA™ (ramucirumab) as
a single-agent treatment for patients with advanced gastric cancer
after prior chemotherapy, making this the first approved product
from Dyax’s LFRP.
For additional information about Dyax, please visit
www.dyax.com.
For additional information about KALBITOR, including full
prescribing information, please visit www.KALBITOR.com.
Disclaimer
This press release contains forward-looking statements.
Statements that are not historical facts are based on Dyax’s
current expectations, beliefs, assumptions, estimates, forecasts
and projections about the industry and markets in which Dyax
operates. The statements contained in this release are not
guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed in such forward-looking statements because of
risks, uncertainties and assumptions involved in any future
projections. There are many factors that could cause actual results
to differ from these forward-looking statements, including: risks
and uncertainties relating to the clinical development of DX-2930;
Dyax’s dependence on the expertise, effort, priorities and
contractual obligations of third parties in the development of
DX-2930 and in the marketing, sales and distribution of KALBITOR;
competition from new and existing treatments for HAE; the
uncertainty of patent and intellectual property protection relating
to DX-2930, KALBITOR and the LFRP; uncertainties and assumptions
relating to the effort, priorities and contractual obligations of
LFRP licensees; and other risk factors described or referred to in
Item 1A, “Risk Factors” in Dyax’s most recent Annual Report on Form
10-K and other periodic reports filed with the Securities and
Exchange Commission. Dyax cautions investors not to place undue
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this
release, and Dyax undertakes no obligations to update or revise
these statements, except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered marks
of Dyax Corp.
Dyax Corp.Jennifer Robinson, 617-250-5741Director, Investor
Relationsand Corporate Communicationsjrobinson@dyax.com
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Apr 2024 to May 2024
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From May 2023 to May 2024